Clinical Trial Update: Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy [Phase 2]

View source ↗

Summary

Phase 2 trial update exploring genomics-based targeted therapy for children with relapsed or refractory malignancies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Solid Tumor

Snippet

Sponsor: Samsung Medical Center | Conditions: Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor | Phase 2 | Status: UNKNOWN